256 related articles for article (PubMed ID: 20686035)
41. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays.
Wang Q; Sun Y; Xu Y; Wang Y; Wang H; Fu Y; Allain JP; Li C; Li T
Viral Immunol; 2019 Oct; 32(8):348-354. PubMed ID: 31433272
[TBL] [Abstract][Full Text] [Related]
42. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
43. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
Kahl CA; Bonnell J; Hiriyanna S; Fultz M; Nyberg-Hoffman C; Chen P; King CR; Gall JG
Vaccine; 2010 Aug; 28(35):5691-702. PubMed ID: 20600496
[TBL] [Abstract][Full Text] [Related]
44. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.
Hensley SE; Giles-Davis W; McCoy KC; Weninger W; Ertl HC
J Immunol; 2005 Nov; 175(9):6032-41. PubMed ID: 16237098
[TBL] [Abstract][Full Text] [Related]
45. Correlates of Protection Against SIV
Tuyishime S; Haut LH; Kurupati RK; Billingsley JM; Carnathan D; Gangahara S; Styles TM; Xiang Z; Li Y; Zopfs M; Liu Q; Zhou X; Lewis MG; Amara RR; Bosinger S; Silvestri G; Ertl HCJ
EBioMedicine; 2018 May; 31():25-35. PubMed ID: 29685793
[TBL] [Abstract][Full Text] [Related]
46. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
47. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.
Wortmann A; Vöhringer S; Engler T; Corjon S; Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Jan; 16(1):154-62. PubMed ID: 17848961
[TBL] [Abstract][Full Text] [Related]
48. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
Front Immunol; 2018; 9():3175. PubMed ID: 30713538
[No Abstract] [Full Text] [Related]
49. Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.
Liu M; Tian X; Li X; Zhou Z; Li C; Zhou R
PLoS One; 2014; 9(7):e103058. PubMed ID: 25054273
[TBL] [Abstract][Full Text] [Related]
50. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
Thomas MA; Song R; Demberg T; Vargas-Inchaustegui DA; Venzon D; Robert-Guroff M
PLoS One; 2013; 8(10):e76344. PubMed ID: 24143187
[TBL] [Abstract][Full Text] [Related]
51. Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.
Fedosyuk S; Merritt T; Peralta-Alvarez MP; Morris SJ; Lam A; Laroudie N; Kangokar A; Wright D; Warimwe GM; Angell-Manning P; Ritchie AJ; Gilbert SC; Xenopoulos A; Boumlic A; Douglas AD
Vaccine; 2019 Nov; 37(47):6951-6961. PubMed ID: 31047679
[TBL] [Abstract][Full Text] [Related]
52. Characterization of a Species E Adenovirus Vector as a Zika virus vaccine.
Bullard BL; Corder BN; Gordon DN; Pierson TC; Weaver EA
Sci Rep; 2020 Feb; 10(1):3613. PubMed ID: 32107394
[TBL] [Abstract][Full Text] [Related]
53. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.
Bayer W; Tenbusch M; Lietz R; Johrden L; Schimmer S; Uberla K; Dittmer U; Wildner O
J Virol; 2010 Feb; 84(4):1967-76. PubMed ID: 20007267
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
[TBL] [Abstract][Full Text] [Related]
55. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
58. Creation of a panel of vectors based on ape adenovirus isolates.
Roy S; Medina-Jaszek A; Wilson MJ; Sandhu A; Calcedo R; Lin J; Wilson JM
J Gene Med; 2011 Jan; 13(1):17-25. PubMed ID: 21259405
[TBL] [Abstract][Full Text] [Related]
59. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.
Tan WG; Jin HT; West EE; Penaloza-MacMaster P; Wieland A; Zilliox MJ; McElrath MJ; Barouch DH; Ahmed R
J Virol; 2013 Feb; 87(3):1359-72. PubMed ID: 23175355
[TBL] [Abstract][Full Text] [Related]
60. Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.
Yu B; Dong J; Wang C; Wang Z; Gao L; Zhang H; Wu J; Kong W; Yu X
J Gen Virol; 2014 Jul; 95(Pt 7):1564-1573. PubMed ID: 24764358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
